Last €4.32 EUR
Change Today +0.015 / 0.35%
Volume 64.8K
MDXH On Other Exchanges
Symbol
Exchange
EN Brussels
As of 6:41 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

mdxhealth (MDXH) Snapshot

Open
€4.31
Previous Close
€4.30
Day High
€4.40
Day Low
€4.30
52 Week High
03/19/14 - €5.29
52 Week Low
05/17/13 - €1.92
Market Cap
147.8M
Average Volume 10 Days
146.1K
EPS TTM
€-0.35
Shares Outstanding
34.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MDXHEALTH (MDXH)

Related News

No related news articles were found.

mdxhealth (MDXH) Related Businessweek News

No Related Businessweek News Found

mdxhealth (MDXH) Details

MDxHealth SA, a molecular diagnostics company, engages in the development and commercialization of epigenetic tests and services for cancer assessment, and the personalized treatment of patients. The company offers clinical molecular diagnostics solutions that provide physicians with assays for the identification and treatment of their cancer patients; and pharmaco molecular diagnostics solutions for the development of companion diagnostics, biomarker discovery, and clinical trial testing. Its product pipeline consists of ConfirmMDx that serve as an aid for physicians to assess DNA methylation status associated with presence or absence of cancer; InformMDx, which provide prognostic assessment to distinguish between aggressive and non-aggressive tumors; and PredictMDx that offer predictive information to indicate which drug or treatment regimen is likely to be most effective for the individual patient. The company’s ClinicalMDx products focus on three cancer areas, such as prostate, colorectal, and lung cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA on October 2010. MDxHealth SA was founded in 2003 and is headquartered in Liège, Belgium.

Founded in 2003

mdxhealth (MDXH) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €462.0K
Compensation as of Fiscal Year 2012.

mdxhealth (MDXH) Key Developments

MDxHealth and LI PATH Announce Marketing Agreement for ConfirmMDx for Prostate Cancer

MDxHealth SA announced that it has entered into a co-marketing agreement with LI PATH (Long Island Pathology Inc.) to promote MDxHealth's ConfirmMDx(R) for Prostate Cancer test. LI PATH is a high-end, full-service independent anatomic and clinical pathology laboratory that serves the New York City metropolitan area. The agreement expands MDxHealth's access to urologists in the highly populated New York and New Jersey region.

MDxHealth SA Presents at KBC Healthcare Conference, Mar-20-2014 11:00 AM

MDxHealth SA Presents at KBC Healthcare Conference, Mar-20-2014 11:00 AM. Venue: KBC Building, Grand Place, Grote Markt 17, 1000 Brussels, Belgium. Speakers: Jan Groen, Chief Executive Officer and Executive Director.

MDxHealth SA's Predictmdx for Glioblastoma Identifies Newly Diagnosed Patients with Improved Progression Free and Overall Survival

MDxHealth SA announced that the publication in the New England Journal of Medicine of a phase III randomized trial of bevacizumab, brand name Avastin(R), for newly diagnosed glioblastoma patients, confirms the clinical utility of its PredictMDx(R) for Glioblastoma test. The company's PredictMDx for Glioblastoma (MGMT) test, included in the 2013 National Comprehensive Cancer Network (NCCN) Senior Adult Oncology Guidelines, provides actionable information to oncologists seeking to provide personalized treatment of elderly patients with glioblastoma (GBM), the most common and most aggressive malignant primary brain tumor in humans. The test assesses the methylation status of the MGMT gene, which is a key DNA repair component. If the MGMT gene is methylated, cancer patients have shown improved response to alkylating drug therapy. Studies on thousands of clinical trial patients have demonstrated that PredictMDx for Glioblastoma can help oncologists identify newly diagnosed glioblastoma patients that are likely to respond to the most commonly used class of brain cancer drugs (alkylating agents). In phase III study patients were prospectively randomized into the treatment arms based on the company's MGMT (O6-methylguanine-DNA methyl transferase) methylation test results. MGMT methylation status was shown to be prognostic for progression-free survival (PFS) and overall survival (OS), regardless of therapies investigated in this study. The median PFS for patients with unmethylated tumors was 8.2 months vs. 14.1 months in the patients with MGMT methylated tumors, with a hazard ratio of 1.67 (95% CI of 1.36 to 2.05, p<0.001). The median OS for patients with MGMT unmethylated tumors was 14.3 months compared with 23.2 months in patients with MGMT methylated tumors. The hazard ratio for death in patients with unmethylated tumors was reported as 2.10 (95% CI of 1.65 to 2.68, p<0.001).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDXH:BB €4.32 EUR +0.015

MDXH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Diagnocure Inc C$0.19 CAD 0.00
Health Discovery Corp $0.03 USD 0.00
LipoScience Inc $3.06 USD +0.03
Miraculins Inc C$0.23 CAD +0.005
Vermillion Inc $2.81 USD +0.125
View Industry Companies
 

Industry Analysis

MDXH

Industry Average

Valuation MDXH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.7x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MDXHEALTH, please visit www.mdxhealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.